Yasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, Jiacai Cho, Worawit Louthrenoo, Alberta Hoi, Vera Golder, Chak Sing Lau, Aisha Lateef, Yi-Hsing Chen, Shue-Fen Luo, Yeong-Jian Jan Wu, Laniyati Hamijoyo, Zhanguo Li, Sargunan Sockalingam, Sandra Navarra, Leonid Zamora, Yanjie Hao, Zhuoli Zhang, Madelynn Chan, Shereen Oon, Kristine Ng, Jun Kikuchi, Tsutomu Takeuchi, Fiona Goldblatt, Sean O'Neill, Nicola Tugnet, Annie Hui Nee Law, Sang-Cheol Bae, Yoshiya Tanaka, Naoaki Ohkubo, Sunil Kumar, Rangi Kandane-Rathnayake, Mandana Nikpour, Eric F Morand
OBJECTIVES: To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE). METHODS: Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ defined as the state with serological activity (increased anti-dsDNA and/or hypocomplementemia) but without clinical activity, treated with ≤7...
February 29, 2024: Annals of the Rheumatic Diseases